Testing a new treatment for progressive supranuclear palsy

Plain-English translation of NCT07498426 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated September 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This is a large study testing whether NIO752, a new medication, can help slow the progression of progressive supranuclear palsy (PSP-RS), a rare neurological condition. Participants will be randomly assigned to receive either the medication or a placebo (a dummy treatment with no active ingredient) and their symptoms will be carefully monitored over time. After the main study period, those who received the medication will have the option to continue taking it.

Progressive supranuclear palsy is a serious condition with limited treatment options, and there is no cure currently available. This trial is testing whether this medication could slow disease progression and improve quality of life for people living with this condition.

Do you qualify?

You likely qualify if…

you are between 41 and 81 years old
you have been diagnosed with mild-to-moderate progressive supranuclear palsy (Richardson syndrome) within the past 5 years
you are able to walk at least 10 steps on your own or with minimal help
you have a reliable study partner (like a spouse, family member, or close friend) who can spend at least 5 hours per week with you and attend visits
you score 20 or higher on a cognitive screening test at the start of the study

You likely don't qualify if…

you have been diagnosed with other neurological or psychiatric conditions such as Parkinson's disease, Alzheimer's disease, or severe depression
you have a history of significant brain injury, stroke, or bleeding in the brain
you have metal implants or a pacemaker that is not compatible with MRI scans
you have a known allergy to local anesthesia or medical conditions that would prevent you from having a lumbar puncture (spinal tap)
you have significant spinal deformities or recent back surgery that would make a spinal tap unsafe

What participation looks like

You will be randomly assigned to receive either the medication or a placebo in liquid form. Neither you nor the researchers will know which treatment you are receiving. You will visit the research site regularly so doctors can monitor your symptoms, perform physical and cognitive tests, and check your safety. The study also includes a lumbar puncture (spinal tap) to collect cerebrospinal fluid and brain MRI scans. After the main study period ends, if you received the medication, you will be invited to continue taking it in an open-label extension, where both you and the researchers will know you are receiving the active treatment.

AI-generated summary from trial data · Sep 24, 2026 · Not medical advice

Trial locations(42 sites)

United States

Mayo Clinic Arizona, Scottsdale, Arizona

Univ of California San Francisco, San Francisco, California

CenExcel Rocky Mtn Clin Research, Englewood, Colorado

Mayo Jacksonville, Jacksonville, Florida

Mayo Clinic, Rochester, Minnesota